2024
Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition.
Lo Y, Lester S, Ellis I, Lanjewar S, Laurini J, Patel A, Bhattarai A, Ustun B, Harmon B, Kleer C, Ross D, Amin A, Wang Y, Bradley R, Turashvili G, Zeng J, Baum J, Singh K, Hakima L, Harigopal M, Komforti M, Shin S, Abbott S, Jaffer S, Badve S, Khoury T, D'Alfonso T, Ginter P, Collins V, Towne W, Gan Y, Nassar A, Sahin A, Flieder A, Aldrees R, Ngo M, Edema U, Sapna F, Schnitt S, Fineberg S. Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition. Archives Of Pathology & Laboratory Medicine 2024, 148: 1119-1125. PMID: 38244086, DOI: 10.5858/arpa.2023-0163-oa.Peer-Reviewed Original ResearchInvasive breast cancerWorld Health Organization definitionNottingham grading systemOrganization definitionMedian concordance rateMicropapillary carcinomaMucinous carcinomaInvasive carcinomaBreast pathologistsBreast cancerConcordance rateGrading systemCarcinomaTubulesPathologistsBreastConcordanceProfessor EllisCancerCases
2020
Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer
Harigopal M, Kowalski D, Vosoughi A. Enumeration and molecular characterization of circulating tumor cells as an innovative tool for companion diagnostics in breast cancer. Expert Review Of Molecular Diagnostics 2020, 20: 815-828. PMID: 32546017, DOI: 10.1080/14737159.2020.1784009.Peer-Reviewed Original ResearchConceptsBreast cancerTumor cellsCTC enumerationCTC detectionCTC clustersMetastatic breast cancerBreast cancer patientsEnumeration of CTCsOverall survivalRisk stratificationMetastatic sitesPeripheral bloodCancer patientsCTC levelsClinical backgroundPrimary siteClinical useCancerTumor phenotypeCompanion diagnosticsTumor heterogeneityDistant sitesMolecular characterizationPatientsPredictive importance
2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original Research
2006
Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays
Dolled-Filhart M, Rydén L, Cregger M, Jirström K, Harigopal M, Camp RL, Rimm DL. Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research 2006, 12: 6459-6468. PMID: 17085660, DOI: 10.1158/1078-0432.ccr-06-1383.Peer-Reviewed Original ResearchConceptsBreast cancerPatient outcomesTissue microarraySubset of patientsBreast cancer patientsTissue microarray platformInternal validation setRoutine pathology laboratoriesCancer patientsEstrogen receptorTissue biomarkersIndependent cohortTumor subtypesPredictive valueAcid-base analysisPathology laboratoryRNA expression studiesCancerTissue sectionsPatientsCohortOutcomesFurther validationObjective quantitative analysisBiomarker discovery
2004
Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer
Psyrri A, Bamias A, Yu Z, Markakis S, Kowalski D, Weinberger P, Harigopal M, Efstathiou E, Rimm D, Dimopoulos M. Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer. Journal Of Clinical Oncology 2004, 22: 5066-5066. DOI: 10.1200/jco.2004.22.14_suppl.5066.Peer-Reviewed Original ResearchMolecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer
Psyrri A, Bamias A, Yu Z, Markakis S, Kowalski D, Weinberger P, Harigopal M, Efstathiou E, Rimm D, Dimopoulos M. Molecular predictors for response to carboplatinum and paclitaxel (CP) chemotherapy in patients with ovarian cancer. Journal Of Clinical Oncology 2004, 22: 5066-5066. DOI: 10.1200/jco.2004.22.90140.5066.Peer-Reviewed Original Research